Ventures
Invest in breakthrough healthtech solutions that transform patients' lives.

Receive the latest investment opportunities that match your interests, directly in your inbox. Stay informed and never miss out.
a highlight from our portfolio

Angiogenesis Analytics

PEP Health
Foveo Fertility addresses the challenge of improving in vitro fertilization (IVF) success rates by providing a stable physiological environment for egg cells. Unlike current methods that expose egg cells to air, leading to cooling and evaporation, Foveo Fertility ensures consistent conditions for optimal egg cell quality. This innovation also streamlines workflow in the IVF lab, reducing human error and saving time for embryologists. With no other product on the market offering constant physiological conditions for egg cells, Foveo Fertility aims to improve the lives of both lab workers and patients by maximizing the potential for successful pregnancies.

Implant Preservation Devices has developed a handheld device to tackle a common problem after joint replacement surgeries prosthetic joint infections (PJI). This device applies heat to implants using induction, effectively targeting and eliminating bacteria that cause these infections. By reducing the risk of recurrent infections, it offers a quick, sterile, and convenient treatment option during surgery, potentially benefiting patients beyond just those undergoing joint replacements.

Introducing LarynxLock, prevents air leaks during surgery with a gentle pressure on the mouth's base, ensuring patients receive uninterrupted air supply. LarynxLock not only safeguards patients from complications but also reduces physical strain and surgery duration, offering a smart and cost-effective solution for improved surgical outcomes.

TherageniX introduces an approach to improve bone implants by augmenting autologous bone grafts with regenerative gene therapies. Traditional bone repair methods face challenges like rejection, infection, and limited regenerative capacity. TherageniX's solution aims to enhance the regenerative bone grafts, improving functional outcomes and reducing donor trauma. This method bypasses regulatory and manufacturing hurdles, offering a promising advancement in bone grafting procedures.

Axial Orthopaedics Inc. revolutionizes trauma treatment with their innovative intramedullary nailing system. Current systems often lead to bone misalignment and joint pain, blocking post-procedural recovery. Axial Orthopaedics's modular system offers greater flexibility in bone alignment and healing. This system not only addresses postoperative pain but also reduces complications. Its intra-operative modularity and rotational capabilities allow surgeons to achieve better fracture fixation and improved outcomes, filling a crucial gap in current technology.

Innofuse is revolutionizing care for the most fragile among us: preterm infants in Neonatal Intensive Care Units (NICUs). Their innovative Tulive® IV-set ensures these tiny patients receive medication with precision and immediacy, sparing them from the risks of inaccurate or delayed drug administration. By reducing fluctuations and eliminating overshoot, Tulive® safeguards against potential brain damage, offering hope and reassurance to families in NICUs worldwide.

ChARM, or the Children’s Automated Respiration Monitor, addresses the challenge of pneumonia misdiagnosis in low-resource settings. This battery-powered device provides accurate breathing rate monitoring for children under five, empowering healthcare workers to make correct diagnoses swiftly. By streamlining the diagnostic process, ChARM facilitates timely treatment, potentially saving thousands of young lives annually.

Respiosa offers a groundbreaking solution for obstructive sleep apnea (OSA), a condition affecting millions worldwide. Unlike traditional treatments like CPAP or surgery, Respiosa provides a minimally invasive, surgically implanted solution specifically targeting tongue-based obstruction, a common cause of OSA. Developed by Philips, Respiosa promises effective, durable, and adjustable therapy with a quick recovery time. With its natural and unobtrusive design, Respiosa ensures high patient adherence, addressing a significant gap in OSA treatment options.

Our impact
Explore our 2024 Impact report

Invest in a portfolio of companies
